The science behind albumin engineering to improve drug efficacy and tolerability
Developers of many peptide and protein drugs frequently face PK and PD challenges that can limit the effectiveness of their drugs due to clearance from the circulatory system.
Resolution of these issues can require frequent and/or high dose levels to succeed in the development process. Both frequent dosing and high dose levels can be detrimental to patient compliance and acceptance as well possible negative side effects/dangers associated with high dosing.
Dr Darrell Sleep,
Director, Biopharma R&D
Sleep has nearly 30 years of experience in Biopharma discovery and development. His team has developed processes for the production of recombinant human albumin, albumin fusions, bioengineered albumins, transferrin and antibody fragments.
Current research is directed at controlling the half-life of peptides and proteins through engineered albumins with modulated affinity for the neonatal Fc receptor.
- How albumin variants have the potential to deliver once-monthly dosing of peptide and protein drugs
- The science behind the use of albumin is well understood and is being widely used in a range of drugs
- How the technology is clinically and commercially validated
- A study of Novozymes as a credible provider of this ground-breaking drug delivery technology
- R&D Drug Development Scientists
- Team Leaders
- Department Heads
- VPs
- Technology Scouts
- Evaluators
- In-Licensing Professionals
